MaxCyte (MXCT) has released an update.
MaxCyte Inc., a leader in cell-engineering technologies, announced the issuance of 135,989 shares of common stock following the exercise of share options and vesting of restricted stock units. This brings the company’s total issued stock capital to 105,434,869 shares, affecting shareholder calculations for stock interest notifications. Investors in the burgeoning cell-based therapeutics market may find this update crucial for evaluating their positions.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.
